Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2020

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

, (1, 2) , (3) , (4) , , , (5, 6) , , (7) , , , (8, 9) , (10, 11, 12) , (13) , , , , , (14)
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Dates et versions

hal-03606393 , version 1 (11-03-2022)

Identifiants

Citer

Eytan M. Stein, Stephane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L. Liesveld, et al.. Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2020, 136 (1), ⟨10.1182/blood-2020-134602⟩. ⟨hal-03606393⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More